Minoryx Therapeutics receives Orphan Drug Designation from the US FDA for its lead candidate MIN-102

by Professional Newco

MIN-102 targets X-linked Adrenoleukodystrophy (X-ALD), a life threatening orphan CNS disease with high unmet medical need. Orphan drug status for MIN-102 has now been granted by both the FDA and the E...

Read more
Subscribe to Directory
Write an Article

Highlight

Interview with Dámaso Molero, general m...

by 3P Biopharmaceuticals

Dámaso Molero: “There are great opportunities in Latin America for ...

Diseñan un método diagnóstico alterna...

by DiCYT - Agencia Iberoamericana para la Difusión de la Ciencia y la Tecnología

Se fundamenta en el análisis automático de una sola señal, la satur...

Photos Stream